Q-omics provides the consensus-scored RPL32P20 profile across patient tissues and cancer cell-line models. RPL32P20 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, RPL32P20 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, RPL32P20 RNA expression shows 9,739 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight BRCA, HNSC, and ESCA as cancer lineages where RPL32P20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL32P20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL32P20 survival associations across molecular data types. RPL32P20 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL32P20 RNA expression–survival associations across cancer types. High RPL32P20 expression shows unfavorable associations in BRCA, LIHC, HNSC and ACC, but favorable associations in OV and READ. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for RPL32P20 RNA expression.
This table summarizes RPL32P20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL32P20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL32P20 shows higher tumor expression in HNSC, KIRC, LUSC, BRCA, LUAD and LIHC. The HNSC box plot shows higher RPL32P20 RNA expression in tumor versus normal tissue (log2 FC = +0.951, t-test p < 0.001).
This table shows molecular features associated with RPL32P20 in patient tissues and cancer cell lines. In patient samples, RPL32P20 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
